EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

High Exposure to Perfluoroalkyl Substances and Antibody Responses to SARS-CoV-2 mRNA Vaccine—an Observational Study in Adults from Ronneby, Sweden

Axel G Andersson iD, Anna Lundgren, Yiyi Xu, Christel Nielsen, Christian H Lindh, Daniela Pineda, Julia Cederlund, Elisavet Pataridou, Sandra Søgaard Tøttenborg, Kajsa Ugelvig Petersen, Tony Fletcher, Martin Lagging und 3 weitere

Environmental Health Perspectives · 2023

DOI: 10.1289/ehp11847 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Environmental Health Perspectives, 2023. Verfasst von Axel G Andersson und 14 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. Hauptthemen laut MEDLINE: COVID-19, Alkanesulfonic Acids, Vaccines, Fluorocarbons. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Per- and polyfluoroalkyl substances (PFAS) are widely used, environmentally ubiquitous, and stable chemicals that have been associated with lower vaccine-induced antibody responses in children; however, data on adults are limited. The drinking water from one of the two waterworks in Ronneby, Sweden, was heavily contaminated for decades with PFAS from firefighting foams, primarily perfluorohexane sulfonic acid and perfluorooctanesulfonic acid (PFOS). Vaccination against SARS-CoV-2 offered a unique opportunity to investigate antibody responses to primary vaccination in adults who had been exposed to PFAS. OBJECTIVES: Our objective was to evaluate associations between PFAS, across a wide range of exposure levels, and antibody responses in adults 5 wk and 6 months after a two-dose vaccination regime against SARS-CoV-2. METHODS: Adults age 20-60 y from Ronneby (n=309, median PFOS serum level 47 ng/mL, fifth to 95th percentile 4-213 ng/mL) and a group with background exposure (n=47, median PFOS serum level 4 ng/mL) received two doses of the Spikevax (Moderna) mRNA vaccine. The levels of seven PFAS were measured in serum before vaccination. Serum immunoglobulin G antibodies against the SARS-CoV-2 spike antigen (S-Abs) were measured before vaccination and at 5 wk (n=350) and 6 months (n=329) after the second vaccine dose. Linear regression analyses were fitted against current, historical, and prenatal exposure to PFAS, adjusting for sex, age, and smoking, excluding individuals with previous SARS-CoV-2-infection. RESULTS: PFAS exposure, regardless of how it was estimated, was not negatively associated with antibody levels 5 wk [current PFOS: -0.5% S-Abs/PFOS interquartile range (IQR); 95% confidence interval (CI): -8, 7] or 6 months (current PFOS: 3% S-Abs/PFOS IQR; 95% CI: -6, 12) after COVID-19 vaccination. DISCUSSION: Following a strict study protocol, rigorous study design, and few dropouts, we found no indication that PFAS exposure negatively affected antibody responses to COVID-19 mRNA vaccination for up to 6 months after vaccination. https://doi.org/10.1289/EHP11847.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Alkanesulfonic AcidsVaccinesFluorocarbonsChildHumansAdultYoung AdultMiddle AgedCOVID-19 VaccinesSARS-CoV-2SwedenAntibody FormationmRNA Vaccines

Substanzen

COVID-19 VaccinesAlkanesulfonic AcidsVaccinesFluorocarbonsmRNA Vaccinesperfluorooctane sulfonic acid

Autor:innen und Institutionen

  • School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Department of Clinical Immunology and Transfusion Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Division of Occupational and Environmental Medicine, Department of Laboratory Medicine, Lund University, Lund, Sweden.
  • Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.
  • Region Blekinge, Karlskrona, Sweden.

ORCID-Profile: Axel G Andersson

Zitieren

APA

Andersson, A. G., Lundgren, A., Xu, Y., Nielsen, C., Lindh, C. H., Pineda, D., Cederlund, J., Pataridou, E., Søgaard Tøttenborg, S., Ugelvig Petersen, K., Fletcher, T., Lagging, M., Bemark, M., Jakobsson, K., & Li, Y. (2023). High Exposure to Perfluoroalkyl Substances and Antibody Responses to SARS-CoV-2 mRNA Vaccine—an Observational Study in Adults from Ronneby, Sweden. Environmental Health Perspectives. https://doi.org/10.1289/ehp11847

Vancouver

Andersson AG, Lundgren A, Xu Y, Nielsen C, Lindh CH, Pineda D, et al. High Exposure to Perfluoroalkyl Substances and Antibody Responses to SARS-CoV-2 mRNA Vaccine—an Observational Study in Adults from Ronneby, Sweden. Environmental Health Perspectives. 2023. doi:10.1289/ehp11847

BibTeX
@article{Andersson2023,
  author = {Andersson, Axel G and Lundgren, Anna and Xu, Yiyi and Nielsen, Christel and Lindh, Christian H and Pineda, Daniela and Cederlund, Julia and Pataridou, Elisavet and Søgaard Tøttenborg, Sandra and Ugelvig Petersen, Kajsa and Fletcher, Tony and Lagging, Martin and Bemark, Mats and Jakobsson, Kristina and Li, Ying},
  title = {High Exposure to Perfluoroalkyl Substances and Antibody Responses to SARS-CoV-2 mRNA Vaccine—an Observational Study in Adults from Ronneby, Sweden},
  journal = {Environmental Health Perspectives},
  year = {2023},
  doi = {10.1289/ehp11847}
}
Kostenlos starten →